{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["1(4)"],"submitter":["Molony DA"],"pubmed_abstract":["<h4>Background</h4>Combination therapy with multiple phosphate binders is prescribed to reduce elevated serum phosphorus (sP) concentrations among patients on maintenance hemodialysis. Sucroferric oxyhydroxide (SO), an iron-based phosphate binder, has demonstrated efficacy at reducing sP while also being associated with a low pill burden. Whereas the effects of SO monotherapy have been well characterized in clinical trials and observational cohorts, little is known about the effects of SO-containing combination therapy.<h4>Methods</h4>Patients on hemodialysis (<i>N</i>=234) at Fresenius Kidney Care (FKC) who received ≥120 days of uninterrupted phosphate binder combination therapy with SO were included in this retrospective study. Patient data were censored after SO discontinuation, end of "],"journal":["Kidney360"],"pagination":["263-272"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8809266"],"repository":["biostudies-literature"],"pubmed_title":["Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients."],"pmcid":["PMC8809266"],"pubmed_authors":["Parameswaran V","Molony DA","Kossmann RJ","Ficociello LH","Mullon C"],"additional_accession":[]},"is_claimable":false,"name":"Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients.","description":"<h4>Background</h4>Combination therapy with multiple phosphate binders is prescribed to reduce elevated serum phosphorus (sP) concentrations among patients on maintenance hemodialysis. Sucroferric oxyhydroxide (SO), an iron-based phosphate binder, has demonstrated efficacy at reducing sP while also being associated with a low pill burden. Whereas the effects of SO monotherapy have been well characterized in clinical trials and observational cohorts, little is known about the effects of SO-containing combination therapy.<h4>Methods</h4>Patients on hemodialysis (<i>N</i>=234) at Fresenius Kidney Care (FKC) who received ≥120 days of uninterrupted phosphate binder combination therapy with SO were included in this retrospective study. Patient data were censored after SO discontinuation, end of ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2025-04-04T03:20:06.177Z","creation":"2025-04-04T03:20:06.177Z"},"accession":"S-EPMC8809266","cross_references":{"pubmed":["35372921"],"doi":["10.34067/kid.0000332019","10.34067/KID.0000332019"]}}